Dainippon Sumitomo Pharma Co., Ltd. and Sepracor Inc. have entered into a definitive agreement under which DSP will acquire Sepracor for approximately $2.6 billion in cash. The boards of directors of both companies approved the transaction. Sepracor will become a wholly owned subsidiary of Dainippon Sumitomo Pharma America Holdings, Inc., a U.S. subsidiary of DSP, and will continue its operations based in Marlborough, MA and in Canada. Sepracor will retain its name, branding and intellectual pro...